Column Group IV GP, LP, 10%, reported an open-market or private purchase at Eikon Therapeutics, Inc. involving 89200.000000 shares for an estimated $1031044.96. Reported holdings after the transaction were 89200.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.
Form 4 relationship flags and nearby filing context
No officer title
The price reported in column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $11.17 to $11.64. The Reporting Person undertakes to provide t…
The securities are directly held by Peter Svennilson.
The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investme…
The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect…
The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG…
0 other filings
0 recent txs